Falcon deep research report on human GATD3 (P0DPI2).
-
GATD3A localizes primarily to the mitochondrial matrix with a smaller intermembrane-space pool; mitochondrial import depends on a cleaved N-terminal targeting signal.
"Experimental fractionation and STED microscopy place GATD3A **primarily in the mitochondrial matrix**, with a smaller **intermembrane-space** pool"
-
GATD3A is a mitochondrial matrix deglycase that removes early glycation adducts on nucleotides and proteins; conserved E62 and C176 form the catalytic core.
"Conserved catalytic residues include **E62** and **C176** in GATD3A; cysteine mutagenesis reduces activity"
-
GATD3A preferentially addresses glyoxal (GO)-derived glycation, whereas DJ-1/PARK7 preferentially handles methylglyoxal (MGO)-derived modifications, suggesting complementary substrate coverage.
"The evidence indicates that GATD3A preferentially addresses **glyoxal (GO)-derived** glycation chemistry, whereas DJ-1/PARK7 preferentially addresses **methylglyoxal (MGO)-derived** modifications under the tested conditions, implying partially complementary substrate coverage."
-
GATD3A co-IPs with mitochondrial mRNA processing and translation factors LRPPRC, SLIRP, and TUFM/EFTu, consistent with positioning near mitochondrial translation machinery.
"Mitochondrial co-immunoprecipitation/proteomics identify GATD3A-associated proteins that include:
- **LRPPRC** and **SLIRP** (mitochondrial mRNA processing/stability)
- **TUFM/EFTu** (mitochondrial translation elongation factor)"
-
GATD3A deficiency drives fibroblast-like synoviocyte senescence and osteoarthritis via enhanced SIRT3-MDH2 binding, MDH2 deacetylation, and impaired TCA cycle flux; rAAV-GATD3A rescues OA in mice.
"GATD3A deficiency increases **SIRT3 binding to MDH2**, leading to **MDH2 deacetylation** and **reduced MDH2 enzymatic activity**, impairing **TCA cycle flux** and driving mitochondrial dysfunction and senescence-associated phenotypes."